Research map: Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study

Back to the article

Papers in this map

  1. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database · Kiyoshi Kubota · 2015 · 314 citations · Cited by this paper
  2. Consensus Recommendations for Management of Darier Disease: A Practical Approach · 2026 · Related
  3. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review · Kevin Yang · 2020 · 189 citations · Cited by this paper
  4. Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy · 2026 · Related
  5. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis · Caitriona Ryan · 2018 · 126 citations · Cited by this paper
  6. Characteristics of Dupilumab-Treated Patients with Atopic Dermatitis Over Time: A Cross-Sectional Assessment of Potential Channeling Bias upon Pediatric Label Extension · 2026 · Related
  7. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study · Tiago Torres · 2021 · 121 citations · Cited by this paper
  8. Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment · 2026 · Related
  9. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta‐analysis · Ahmed I. Mourad · 2019 · 109 citations · Cited by this paper
  10. JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study · 2026 · Related
  11. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database · Laura Pina Vegas · 2022 · 66 citations · Cited by this paper
  12. Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo · 2026 · Related
  13. Female patients are less satisfied with biological treatment for psoriasis and experience more side‐effects than male patients: results from the prospective BioCAPTURE registry · Lara S. van der Schoot · 2019 · 53 citations · Cited by this paper
  14. Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study · 2026 · Related
  15. Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry · Benjamin Lockshin · 2021 · 47 citations · Cited by this paper
  16. Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study · 2026 · Related
  17. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry · Martina Kojanová · 2022 · 36 citations · Cited by this paper
  18. Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region · 2026 · Related
  19. Late-onset development of psoriasis in Japan: a population-based cohort study · Haruka Goto · 2020 · 34 citations · Cited by this paper
  20. Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival · 2026 · Related
  21. Treatment patterns, healthcare resource utilization, and costs in patients with moderate‐to‐severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study · Yayoi Tada · 2022 · 28 citations · Cited by this paper
  22. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials · Atul A. Deodhar · 2024 · 28 citations · Cited by this paper
  23. Out-of-Pocket Costs of Specialty Medications for Psoriasis and Psoriatic Arthritis Treatment in the Medicare Population · Sarah P. Pourali · 2021 · 25 citations · Cited by this paper
  24. Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups · Ros Wade · 2020 · 23 citations · Cited by this paper
  25. Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data · Arno W. R. van Kuijk · 2023 · 21 citations · Cited by this paper
  26. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases · Craig L. Leonardi · 2022 · 17 citations · Cited by this paper
  27. Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan · Yayoi Tada · 2023 · 16 citations · Cited by this paper
  28. Updates on Psoriasis in Special Areas · Alexandra‐Irina Butacu · 2024 · 15 citations · Cited by this paper
  29. Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management · Alaa E. El‐Sisi · 2025 · 14 citations · Cited by this paper
  30. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study · Chaochen Wang · 2023 · 12 citations · Cited by this paper
  31. Treatment practices for psoriasis and how they are changing · Suraj Muddasani · 2020 · 9 citations · Cited by this paper
  32. Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post‐marketing surveillance · Hideshi Torii · 2025 · 5 citations · Cited by this paper
  33. Factors Affecting Treatment Persistence in Japanese Patients with Psoriasis Prescribed Biologics: A Real-World Study Using an Insurance Claim Database · Celine Miyazaki · 2024 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)